Commentary|Podcasts|November 8, 2024
Key Findings of the NIAGARA and HIMALAYA Trials
Author(s)Don Tracy, Associate Editor
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Advertisement
AstraZeneca's Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses:
- Results of the NIAGARA trial in bladder cancer
- The significance of the five-year overall survival data from the HIMALAYA trial, specifically the long-term efficacy of the STRIDE regimen for unresectable liver cancer
- and much more!
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5